{"count": 11, "results": [{"_id": "35152405", "pmid": 35152405, "title": "The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.", "journal": "Clin Pharmacol Ther", "authors": ["Cooper-DeHoff RM", "Niemi M", "Ramsey LB", "Luzum JA", "Tarkiainen EK", "Straka RJ", "Gong L", "Tuteja S", "Wilke RA", "Wadelius M", "Larson EA", "Roden DM", "Klein TE", "Yee SW", "Krauss RM", "Turner RM", "Palaniappan L", "Gaedigk A", "Giacomini KM", "Caudle KE", "Voora D"], "date": "2022-05-01T00:00:00Z", "doi": "10.1002/cpt.2557", "meta_date_publication": "2022 May", "meta_volume": "111", "meta_issue": "5", "meta_pages": "1007-1021", "score": 50252.96, "text_hl": "Genetic variation in each of these genes alters systemic exposure to statins (i.e., @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@, @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@rosuvastatin@@@, @CHEMICAL_Pravastatin @CHEMICAL_MESH:D017035 @@@pravastatin@@@, @CHEMICAL_pitavastatin @CHEMICAL_MESH:C108475 @@@pitavastatin@@@, @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@, @CHEMICAL_Fluvastatin @CHEMICAL_MESH:D000077340 @@@fluvastatin@@@, @CHEMICAL_Lovastatin @CHEMICAL_MESH:D008148 @@@lovastatin@@@), which can increase the risk for @<m>DISEASE_Musculoskeletal_Diseases</m> @DISEASE_MESH:D009140 @@@SAMS@@@. ", "citations": {"NLM": "Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. PMID: 35152405", "BibTeX": "@article{35152405, title={The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.}, author={Cooper-DeHoff RM and Niemi M and Ramsey LB and Luzum JA and Tarkiainen EK and Straka RJ and Gong L and Tuteja S and Wilke RA and Wadelius M and Larson EA and Roden DM and Klein TE and Yee SW and Krauss RM and Turner RM and Palaniappan L and Gaedigk A and Giacomini KM and Caudle KE and Voora D}, journal={Clin Pharmacol Ther}, volume={111}, number={5}, pages={1007-1021}}"}}, {"_id": "35269994", "pmid": 35269994, "pmcid": "PMC8911248", "title": "Simvastatin Downregulates Cofilin and Stathmin to Inhibit Skeletal Muscle Cells Migration", "journal": "Int J Mol Sci", "authors": ["Lin LP", "Yu TY", "Chang HN", "Tsai WC", "Pang JS"], "date": "2022-03-05T00:00:00Z", "doi": "10.3390/ijms23052848", "meta_date_publication": "2022 Mar 5", "meta_volume": "23", "meta_issue": "5", "meta_pages": "", "score": 50251.812, "text_hl": "Given their widespread use, many adverse effects from statins have been reported; of these, @<m>DISEASE_Musculoskeletal_Diseases</m> @DISEASE_MESH:D009140 @@@musculoskeletal complications@@@ occurred in 15% of @SPECIES_9606 @@@patients@@@ after receiving statins for 6 months, and @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ was the most commonly administered statin among these cases. ", "citations": {"NLM": "Lin LP, Yu TY, Chang HN, Tsai WC, Pang JS. Simvastatin Downregulates Cofilin and Stathmin to Inhibit Skeletal Muscle Cells Migration Int J Mol Sci. 2022 Mar 5;23(5):. PMID: 35269994", "BibTeX": "@article{35269994, title={Simvastatin Downregulates Cofilin and Stathmin to Inhibit Skeletal Muscle Cells Migration}, author={Lin LP and Yu TY and Chang HN and Tsai WC and Pang JS}, journal={Int J Mol Sci}, volume={23}, number={5}}"}}, {"_id": "35034348", "pmid": 35034348, "pmcid": "PMC9303592", "title": " SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care", "journal": "Clin Pharmacol Ther", "authors": ["Voora D", "Baye J", "McDermaid A", "Narayana Gowda S", "Wilke RA", "Nicole Myrmoe A", "Hajek C", "Larson EA"], "date": "2022-05-01T00:00:00Z", "doi": "10.1002/cpt.2527", "meta_date_publication": "2022 May", "meta_volume": "111", "meta_issue": "5", "meta_pages": "1075-1083", "score": 50243.98, "text_hl": "The @GENE_SLCO1B1 @GENE_10599 @@@SLCO1B1@@@*5 allele has previously been associated with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ discontinuation and @<m>DISEASE_Musculoskeletal_Diseases</m> @DISEASE_MESH:D009140 @@@SAMSs@@@. ", "citations": {"NLM": "Voora D, Baye J, McDermaid A, Narayana Gowda S, Wilke RA, Nicole Myrmoe A, Hajek C, Larson EA.  SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care Clin Pharmacol Ther. 2022 May;111(5):1075-1083. PMID: 35034348", "BibTeX": "@article{35034348, title={ SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care}, author={Voora D and Baye J and McDermaid A and Narayana Gowda S and Wilke RA and Nicole Myrmoe A and Hajek C and Larson EA}, journal={Clin Pharmacol Ther}, volume={111}, number={5}, pages={1075-1083}}"}}, {"_id": "28951665", "pmid": 28951665, "pmcid": "PMC5605837", "title": "Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction", "journal": "Saudi Pharm J", "authors": ["Siriangkhawut M", "Tansakul P", "Uchaipichat V"], "date": "2017-09-01T00:00:00Z", "doi": "10.1016/j.jsps.2016.12.006", "meta_date_publication": "2017 Sep", "meta_volume": "25", "meta_issue": "6", "meta_pages": "823-829", "score": 50092.336, "text_hl": "The combination of these drugs with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ may potentiate @<m>DISEASE_Musculoskeletal_Diseases</m> @DISEASE_MESH:D009140 @@@musculoskeletal AEs@@@. ", "citations": {"NLM": "Siriangkhawut M, Tansakul P, Uchaipichat V. Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction Saudi Pharm J. 2017 Sep;25(6):823-829. PMID: 28951665", "BibTeX": "@article{28951665, title={Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction}, author={Siriangkhawut M and Tansakul P and Uchaipichat V}, journal={Saudi Pharm J}, volume={25}, number={6}, pages={823-829}}"}}, {"_id": "8339149", "pmid": 8339149, "title": "Musculoskeletal manifestations during simvastatin therapy.", "journal": "Br J Rheumatol", "authors": ["McDonagh J", "Winocour P", "Walker DJ"], "date": "1993-07-01T00:00:00Z", "doi": "10.1093/rheumatology/32.7.647", "meta_date_publication": "1993 Jul", "meta_volume": "32", "meta_issue": "7", "meta_pages": "647-8", "score": 50088.816, "text_hl": "@<m>DISEASE_Musculoskeletal_Diseases</m> @DISEASE_MESH:D009140 @@@Musculoskeletal manifestations@@@ during @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ therapy.", "citations": {"NLM": "McDonagh J, Winocour P, Walker DJ. Musculoskeletal manifestations during simvastatin therapy. Br J Rheumatol. 1993 Jul;32(7):647-8. PMID: 8339149", "BibTeX": "@article{8339149, title={Musculoskeletal manifestations during simvastatin therapy.}, author={McDonagh J and Winocour P and Walker DJ}, journal={Br J Rheumatol}, volume={32}, number={7}, pages={647-8}}"}}, {"_id": "12655157", "pmid": 12655157, "title": "Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients.", "journal": "Circ J", "authors": ["Matsuzawa Y", "Kita T", "Mabuchi H", "Matsuzaki M", "Nakaya N", "Oikawa S", "Saito Y", "Sasaki J", "Shimamoto K", "Itakura H", "J-LIT Study Group"], "date": "2003-04-01T00:00:00Z", "doi": "10.1253/circj.67.287", "meta_date_publication": "2003 Apr", "meta_volume": "67", "meta_issue": "4", "meta_pages": "287-94", "score": 50046.49, "text_hl": "All the enrolled @SPECIES_9606 @@@patients@@@ were treated with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@. The current study analyzed the @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@ lowering effect and safety of the low-dose @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ therapy used in the J-LIT study. ", "citations": {"NLM": "Matsuzawa Y, Kita T, Mabuchi H, Matsuzaki M, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H, J-LIT Study Group. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J. 2003 Apr;67(4):287-94. PMID: 12655157", "BibTeX": "@article{12655157, title={Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients.}, author={Matsuzawa Y and Kita T and Mabuchi H and Matsuzaki M and Nakaya N and Oikawa S and Saito Y and Sasaki J and Shimamoto K and Itakura H and J-LIT Study Group}, journal={Circ J}, volume={67}, number={4}, pages={287-94}}"}}, {"_id": "8348392", "pmid": 8348392, "title": "Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.", "journal": "Can J Cardiol", "authors": ["Frohlich J", "Brun LD", "Blank D", "Campeau L", "Crockford P", "Curnew G", "Dafoe W", "Davignon J", "Dufour R", "Emery G"], "date": "1993-06-01T00:00:00Z", "meta_date_publication": "1993 Jun", "meta_volume": "9", "meta_issue": "5", "meta_pages": "405-12", "score": 50045.574, "text_hl": "Serious adverse events (clinical and laboratory) were reported in four @SPECIES_9606 @@@patients@@@ in the @CHEMICAL_Lovastatin @CHEMICAL_MESH:D008148 @@@lovastatin@@@ group and three in the @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ group. The most reported nonserious adverse effects were @DISEASE_Gastrointestinal_Neoplasms @DISEASE_MESH:D005770 @@@gastrointestinal tract@@@ (15 @SPECIES_9606 @@@patients@@@ in the @CHEMICAL_Lovastatin @CHEMICAL_MESH:D008148 @@@lovastatin@@@ group and 16 in the @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ group) and @<m>DISEASE_Musculoskeletal_Diseases</m> @DISEASE_MESH:D009140 @@@musculoskeletal@@@ (14 @SPECIES_9606 @@@patients@@@ in the @CHEMICAL_Lovastatin @CHEMICAL_MESH:D008148 @@@lovastatin@@@ group and 11 in the @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ group). ", "citations": {"NLM": "Frohlich J, Brun LD, Blank D, Campeau L, Crockford P, Curnew G, Dafoe W, Davignon J, Dufour R, Emery G. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia. Can J Cardiol. 1993 Jun;9(5):405-12. PMID: 8348392", "BibTeX": "@article{8348392, title={Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.}, author={Frohlich J and Brun LD and Blank D and Campeau L and Crockford P and Curnew G and Dafoe W and Davignon J and Dufour R and Emery G}, journal={Can J Cardiol}, volume={9}, number={5}, pages={405-12}}"}}, {"_id": "21742556", "pmid": 21742556, "title": "Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.", "journal": "Lancet Neurol", "authors": ["Sorensen PS", "Lycke J", "Erälinna JP", "Edland A", "Wu X", "Frederiksen JL", "Oturai A", "Malmeström C", "Stenager E", "Sellebjerg F", "Sondergaard HB", "SIMCOMBIN study investigators"], "date": "2011-08-01T00:00:00Z", "doi": "10.1016/S1474-4422(11)70144-2", "meta_date_publication": "2011 Aug", "meta_volume": "10", "meta_issue": "8", "meta_pages": "691-701", "score": 50043.984, "text_hl": "Generally, adverse events were mild and there were no group differences in @DISEASE_Infections @DISEASE_MESH:D007239 @@@infections@@@ or @<m>DISEASE_Musculoskeletal_Diseases</m> @DISEASE_MESH:D009140 @@@musculoskeletal disorders@@@, including @DISEASE_Myalgia @DISEASE_MESH:D063806 @@@myalgia@@@ (five [3%] @SPECIES_9606 @@@patients@@@ on @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ and nine [6%] on placebo). ", "citations": {"NLM": "Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB, SIMCOMBIN study investigators. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011 Aug;10(8):691-701. PMID: 21742556", "BibTeX": "@article{21742556, title={Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.}, author={Sorensen PS and Lycke J and Erälinna JP and Edland A and Wu X and Frederiksen JL and Oturai A and Malmeström C and Stenager E and Sellebjerg F and Sondergaard HB and SIMCOMBIN study investigators}, journal={Lancet Neurol}, volume={10}, number={8}, pages={691-701}}"}}, {"_id": "15308989", "pmid": 15308989, "title": "Treatment of hyperlipidemia in cardiac transplant recipients.", "journal": "Am Heart J", "authors": ["Bilchick KC", "Henrikson CA", "Skojec D", "Kasper EK", "Blumenthal RS"], "date": "2004-08-01T00:00:00Z", "doi": "10.1016/j.ahj.2004.03.050", "meta_date_publication": "2004 Aug", "meta_volume": "148", "meta_issue": "2", "meta_pages": "200-10", "score": 50042.2, "text_hl": "Although the benefit of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ has been shown to extend to 8 years after transplantation, increased adverse effects in other studies with higher doses of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ have resulted in new prescribing recommendations, which state that the dose of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ should probably not exceed 10 mg with @CHEMICAL_Cyclosporine @CHEMICAL_MESH:D016572 @@@cyclosporine@@@ or @CHEMICAL_Gemfibrozil @CHEMICAL_MESH:D015248 @@@gemfibrozil@@@ and 20 mg with @CHEMICAL_Amiodarone @CHEMICAL_MESH:D000638 @@@amiodarone@@@ or @CHEMICAL_Verapamil @CHEMICAL_MESH:D014700 @@@verapamil@@@. ", "citations": {"NLM": "Bilchick KC, Henrikson CA, Skojec D, Kasper EK, Blumenthal RS. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J. 2004 Aug;148(2):200-10. PMID: 15308989", "BibTeX": "@article{15308989, title={Treatment of hyperlipidemia in cardiac transplant recipients.}, author={Bilchick KC and Henrikson CA and Skojec D and Kasper EK and Blumenthal RS}, journal={Am Heart J}, volume={148}, number={2}, pages={200-10}}"}}, {"_id": "9101013", "pmid": 9101013, "title": "The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients.", "journal": "Ann Pharmacother", "authors": ["Southworth MR", "Mauro VF"], "date": "1997-04-01T00:00:00Z", "doi": "10.1177/106002809703100417", "meta_date_publication": "1997 Apr", "meta_volume": "31", "meta_issue": "4", "meta_pages": "489-91", "score": 50041.527, "text_hl": "Although the risk of @<m>DISEASE_Musculoskeletal_Diseases</m> @DISEASE_MESH:D009140 @@@musculoskeletal toxicity@@@ exists at any HMG-CoA reductase inhibitor dosage, most @SPECIES_9606 @@@patients@@@ should be able to tolerate daily dosages of up to 20 mg of @CHEMICAL_Lovastatin @CHEMICAL_MESH:D008148 @@@lovastatin@@@, 10 mg of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@, and 40 mg of @CHEMICAL_Pravastatin @CHEMICAL_MESH:D017035 @@@pravastatin@@@. ", "citations": {"NLM": "Southworth MR, Mauro VF. The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients. Ann Pharmacother. 1997 Apr;31(4):489-91. PMID: 9101013", "BibTeX": "@article{9101013, title={The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients.}, author={Southworth MR and Mauro VF}, journal={Ann Pharmacother}, volume={31}, number={4}, pages={489-91}}"}}]}